Todos Medical receives US FDA certificate of free sale for its new five-day Tollovid dosing regimen

Todos Medical Ltd (OTCQB:TOMDF), a medical diagnostics and related solutions company, revealed that the US Food and Drug Administration (FDA) has granted it a new certificate of free sale for a second dosing regimen for Tollovid as a dietary supplement.

Under the new certificate of free sale, the company is authorized to market Tollovid with a dosing regimen of 60 pills over a five-day period, equivalent to 12 pills per day. Tollovid, a mix of botanical extracts, is being targeted to support healthy immune function against circulating coronaviruses. 

Tollovid’s mechanism of action is to inhibit the activity of the 3CL protease, a key protease required for the intracellular replication of coronaviruses, said the company. Todos sees this new dosing regimen for Tollovid as “optimal for supporting healthy immune function.”

READ: Todos Medical announces commercial launch of its 3CL protease inhibitor dietary supplement Tollovid at The Alchemist’s Kitchen in New York

“We were very pleased with the speed with which this dosing regimen for Tollovid was granted a new Certificate of Free by the FDA,” Todos Medical CEO Gerald E Commissiong said in a statement.

“After a successful initial launch at The Alchemist’s Kitchen in New York City, where we gained significant feedback from customers on what worked best for them with Tollovid, we developed an upgraded dosing regimen based on the first-hand experience of customers that had a successful experience with the product.”

Commissiong said that armed that “critical information,” Todos is preparing to launch its branded Tollovid product in the US market through a soon-to-be-launched website – www.MyTollovid.com

“We also intend to explore opportunities to distribute Tollovid in other areas of the world that are eagerly seeking new products that can potentially inhibit 3CL protease,” added Commissiong.

Todos said it plans to use a portion of the proceeds from a $3.3 million fixed-price crossover investment with Yozma Group, a venture capital firm from South Korea, to launch Tollovid. With Yozma’s recent investment, Todos has raised $9.7 million in the crossover round since January 2021, said the company.

In addition to the Tollovid launch, Todos said it is using the funds to retire outstanding debts and advance ongoing Phase 2 clinical trials of the company’s oral 3CL protease targeting drug candidate Tollovir for hospitalized coronavirus (COVID-19) patients.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Story by ProactiveInvestors